Jubilant Pharmova (530019) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
24 Nov, 2025Executive summary
Achieved 10% year-over-year revenue growth in Q1'FY26, with EBITDA and PAT margin expansion across all business units.
Consolidated revenue from operations for Q1 FY26 was ₹18,789 million, up from ₹17,204 million year-over-year and slightly down from ₹19,158 million sequentially.
Vision 2030 targets doubling revenues, 23–25% EBITDA margin, zero net debt, and high teens ROCE by FY30.
Major growth drivers include expansion in radiopharma, allergy immunotherapy, CDMO sterile injectables, CRDMO, and generics.
The Board approved the sale of the API business to a wholly-owned subsidiary, classifying it as discontinued operations in standalone results.
Financial highlights
Q1'FY26 revenue: Rs. 1,901 Cr, up 10% year-over-year; EBITDA: Rs. 302 Cr, up 14% year-over-year; EBITDA margin: 15.8%.
Total consolidated income for the quarter was ₹19,127 million, with total expenses at ₹17,582 million.
Normalized PAT: Rs. 103 Cr, up 48% year-over-year; Normalized PAT margin: 5.4%.
Net profit attributable to owners for the quarter was ₹1,029 million, compared to ₹4,821 million in Q1 FY25.
All business segments reported year-over-year revenue growth, with notable EBITDA margin improvements in generics and CRDMO.
Outlook and guidance
On track to double revenues by FY30, with EBITDA margin guidance of 23–25% and zero net debt.
The API business sale is expected to complete by 1 September 2025, with no impact on consolidated results as the transaction is intra-group.
Radiopharma and CDMO sterile injectables to drive margin expansion through new product launches and capacity doubling.
Generics and API businesses targeting top quartile profitability and margin improvement.
Proprietary novel drugs to explore monetization via licensing or external funding, with clinical data readouts expected in CY2026.
Latest events from Jubilant Pharmova
- Revenue rose 21%, while lower SPECT supply and costs cut EBITDA 27%.530019
Q2 26/27 - Record FY20 profitability came with COVID-19 disruption and deferred capex.530019
Q4 19/20 - Pharmaceuticals drove record revenue, while the IFC settlement weighed on reported profit.530019
Q4 18/19 - Products growth offset weaker Services as FY11 results absorbed demerger and H1N1 comparisons.530019
Q4 10/11 - Record FY17 results, injectables momentum and lower leverage offset significant operating risks.530019
Q4 16/17 - EBITDA climbed 76% as pharma growth drove a strong FY16 earnings recovery.530019
Q4 15/16 - Record FY18 growth, led by specialty pharma and ingredients, alongside debt reduction and Triad integration.530019
Q4 17/18 - Flat revenue masked weaker earnings; radiopharma growth and FY16 recovery plans offered offsets.530019
Q4 14/15 - Revenue grew 12%, while exceptional costs and sterile-compliance issues weighed on profit.530019
Q4 13/14 - Revenue grew 17%, while SPECT constraints and Montreal costs pressured profitability.530019
Q1 26/27